This work highlights the primary effects of externalities on businesses, organizations, and teams. It then discusses the necessity for adapting and complementing traditional concepts, models, and theories of negotiation in this increasingly diverse and complex nonmarket arena. A third topic focuses...

Sensitive identification of neoantigens and cognate TCRs in human solid tumors.

Articles

M. Arnaud et al.

Articles

The identification of patient-specific tumor antigens is complicated by the low frequency of T cells specific for each tumor antigen. Here we describe NeoScreen, a method that enables the sensitive identification of rare tumor (neo)antigens and of cognate T cell receptors (TCRs) expressed by tumor-i...

Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.

Articles

F.G. Herrera et al.

Articles

Developing strategies to inflame tumors is critical for increasing response to immunotherapy. Here, we report that low-dose radiotherapy (LDRT) of murine tumors promotes T-cell infiltration and enables responsiveness to combinatorial immunotherapy in an IFN-dependent manner. Treatment efficacy relie...

Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes.

Articles

A. Orcurto et al.

Articles

Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TILs) is a promising experimental immunotherapy that has shown high objective responses in patients with melanoma. Current protocols use a lymphodepletive chemotherapy before infusion of ex vivo expanded TILs, followed by high-dose in...

Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells.

Articles

B. Mastelic-Gavillet et al. (10 oct. 2019)

Articles

Several mechanisms are present in the tumor microenvironment (TME) to impair cytotoxic T cell responses potentially able to control tumor growth. Among these, the accumulation of adenosine (Ado) contributes to tumor progression and represents a promising immunotherapeutic target. Ado has been shown...